













3. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 396 (2020): 1204-1222.
4. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet* 375 (2010): 2215-22.
5. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 402 (2023): 203-234.
6. Anjana RM, Baskar V, Nair ATN, et al. Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study. *BMJ Open Diabetes Res Care* 8 (2020): e001506.
7. Kalra S, Mithal A, Zargar AH, et al. Indian Phenotype Characteristics Among Patients with Type 2 Diabetes Mellitus: Insights from a Non-interventional Nationwide Registry in India. *touchREV Endocrinol* 18 (2022): 63-70.
8. Mohan V, Sandeep S, Deepa R, et al. Epidemiology of type 2 diabetes: Indian scenario. *Indian J Med Res* 125 (2007): 217-230.
9. Ruderman N, Chisholm D, Pi-Sunyer X, et al. The metabolically obese, normal-weight individual revisited. *Diabetes* 47 (1998): 699-713.
10. Matheus AS, Tannus LR, Cobas RA, et al. Impact of diabetes on cardiovascular disease: an update. *Int J Hypertens* (2013): 653789.
11. Kosiborod M, Gomes MB, Nicolucci A, et al. DISCOVER investigators. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). *Cardiovasc Diabetol* 17 (2018): 150.
12. Mohan V, Venkatraman JV, Pradeepa R. Epidemiology of cardiovascular disease in type 2 diabetes: the Indian scenario. *J Diabetes Sci Technol* 4 (2010): 158-170.
13. Galindo RJ, Trujillo JM, Low Wang CC, et al. Advances in the management of type 2 diabetes in adults. *BMJ Med* 2 (2023): e000372.
14. Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. *World J Diabetes* 6 (2015):1246-158.
15. Chadha M, Das AK, Deb P, et al. Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i+DPP4i in the Indian Diabetes Setting. *Diabetes Ther* 13 (2022): 1097-1114.
16. Yeh JS, Van Hoof TJ, Fischer MA. Key Features of Academic Detailing: Development of an Expert Consensus Using the Delphi Method. *Am Health Drug Benefits* 9 (2016): 42-50.
17. Anjana RM, Pradeepa R, Unnikrishnan R, et al. New and Unique Clusters of Type 2 Diabetes Identified in Indians. *J Assoc Physicians India* 69 (2021): 58-61.
18. Gan S, Dawed AY, Donnelly LA, et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Diabetes Care* 43 (2020): 1948-1957.
19. Takuma K, Fuchigami A, Shigiyama F, et al. Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub-analysis of the DIVERSITY-CVR study. *Diabetes Obes Metab* 25 (2023): 2131-2141.
20. Bhattacharjee R, Rai M, Joshi P, et al. The Real DAPSI: A Real-World Retrospective Study on Assessing the Efficacy and Safety of a Fixed-Dose Combination of Dapagliflozin and Sitagliptin in the Indian Population. *Cureus* 15 (2023): e46767.
21. Singh AK, Singh A, Singh R. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials. *Endocr Pract* 29 (2023): 509-516.
22. Bjornstad P, Drews KL, Caprio S, et al. Long-Term Complications in Youth-Onset Type 2 Diabetes. *N Engl J Med* 385 (2021): 416-426.
23. Nathan DM, Lachin JM, Bebu I, et al. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. *N Engl J Med* 387 (2022): 1075-1088.
24. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med* 364 (2011): 829-841.